Literature DB >> 15496428

The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway.

Hsien-Yang Lee1, Ying Xu, Yong Huang, Andrew H Ahn, Georg W J Auburger, Massimo Pandolfo, Hubert Kwiecinski, David A Grimes, Anthony E Lang, Jorgen E Nielsen, Yuri Averyanov, Serenella Servidei, Andrzej Friedman, Patrick Van Bogaert, Marc J Abramowicz, Michiko K Bruno, Beatrice F Sorensen, Ling Tang, Ying-Hui Fu, Louis J Ptácek.   

Abstract

Paroxysmal non-kinesigenic dyskinesia (PNKD) is characterized by spontaneous hyperkinetic attacks that are precipitated by alcohol, coffee, stress and fatigue. We report mutations in the myofibrillogenesis regulator 1 (MR-1) gene causing PNKD in 50 individuals from eight families. The mutations cause changes (Ala to Val) in the N-terminal region of two MR-1 isoforms. The MR-1L isoform is specifically expressed in brain and is localized to the cell membrane while the MR-1S isoform is ubiquitously expressed and shows diffuse cytoplasmic and nuclear localization. Bioinformatic analysis reveals that the MR-1 gene is homologous to the hydroxyacylglutathione hydrolase (HAGH) gene. HAGH functions in a pathway to detoxify methylglyoxal, a compound present in coffee and alcoholic beverages and produced as a by-product of oxidative stress. Our results suggest a mechanism whereby alcohol, coffee and stress may act as precipitants of attacks in PNKD. Stress response pathways will be important areas for elucidation of episodic disease genetics where stress is a common precipitant of many common disorders like epilepsy, migraine and cardiac arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15496428     DOI: 10.1093/hmg/ddh330

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  41 in total

1.  Diagnosis and treatment of paroxysmal dyskinesias revisited.

Authors:  Iris Unterberger; Eugen Trinka
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

2.  Long-term improvement of paroxysmal dystonic choreathetosis with acetazolamide.

Authors:  Veronique Michel; Florence Riant; Elisabeth Tournier-Lasserve; Dominique Guehl; Alain Lagueny; Bernard Bioulac; Pierre Burbaud
Journal:  J Neurol       Date:  2006-04-28       Impact factor: 4.849

3.  Synaptic UNC13A protein variant causes increased neurotransmission and dyskinetic movement disorder.

Authors:  Noa Lipstein; Nanda M Verhoeven-Duif; Francesco E Michelassi; Nathaniel Calloway; Peter M van Hasselt; Katarzyna Pienkowska; Gijs van Haaften; Mieke M van Haelst; Ron van Empelen; Inge Cuppen; Heleen C van Teeseling; Annemieke M V Evelein; Jacob A Vorstman; Sven Thoms; Olaf Jahn; Karen J Duran; Glen R Monroe; Timothy A Ryan; Holger Taschenberger; Jeremy S Dittman; Jeong-Seop Rhee; Gepke Visser; Judith J Jans; Nils Brose
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

4.  Dopamine dysregulation in a mouse model of paroxysmal nonkinesigenic dyskinesia.

Authors:  Hsien-yang Lee; Junko Nakayama; Ying Xu; Xueliang Fan; Maha Karouani; Yiguo Shen; Emmanuel N Pothos; Ellen J Hess; Ying-Hui Fu; Robert H Edwards; Louis J Ptácek
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

Review 5.  The epileptic and nonepileptic spectrum of paroxysmal dyskinesias: Channelopathies, synaptopathies, and transportopathies.

Authors:  Roberto Erro; Kailash P Bhatia; Alberto J Espay; Pasquale Striano
Journal:  Mov Disord       Date:  2017-01-16       Impact factor: 10.338

Review 6.  Genetic updates on paroxysmal dyskinesias.

Authors:  James Y Liao; Philippe A Salles; Umar A Shuaib; Hubert H Fernandez
Journal:  J Neural Transm (Vienna)       Date:  2021-04-30       Impact factor: 3.575

7.  GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak.

Authors:  Yvonne G Weber; Alexander Storch; Thomas V Wuttke; Knut Brockmann; Judith Kempfle; Snezana Maljevic; Lucia Margari; Christoph Kamm; Susanne A Schneider; Stephan M Huber; Arnulf Pekrun; Robert Roebling; Guiscard Seebohm; Saisudha Koka; Camelia Lang; Eduard Kraft; Dragica Blazevic; Alberto Salvo-Vargas; Michael Fauler; Felix M Mottaghy; Alexander Münchau; Mark J Edwards; Anna Presicci; Francesco Margari; Thomas Gasser; Florian Lang; Kailash P Bhatia; Frank Lehmann-Horn; Holger Lerche
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

8.  Familial dyskinesia and facial myokymia (FDFM): Follow-up of a large family and linkage to chromosome 3p21-3q21.

Authors:  Wendy H Raskind; Mark Matsushita; Beate Peter; Jeffrey Biberston; John Wolff; Hillary Lipe; Ruben Burbank; Thomas D Bird
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-06-05       Impact factor: 3.568

9.  Infantile convulsions with paroxysmal dyskinesia (ICCA syndrome) and copy number variation at human chromosome 16p11.

Authors:  Patrice Roll; Damien Sanlaville; Jennifer Cillario; Audrey Labalme; Nadine Bruneau; Annick Massacrier; Marc Délepine; Philippe Dessen; Vladimir Lazar; Andrée Robaglia-Schlupp; Gaëtan Lesca; Elisabeth Jouve; Gabrielle Rudolf; Jacques Rochette; G Mark Lathrop; Pierre Szepetowski
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

Review 10.  Episodic movement disorders: from phenotype to genotype and back.

Authors:  Knut Brockmann
Journal:  Curr Neurol Neurosci Rep       Date:  2013-10       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.